Heard JR - Search Results

1

Biomarkers of treatment response in bladder cancer.

Heard JR, Ahdoot M, Theodorescu D, Mitra AP. Heard JR, et al. Expert Rev Mol Diagn. 2024 Oct;24(10):957-969. doi: 10.1080/14737159.2024.2428747. Epub 2024 Nov 13. Expert Rev Mol Diagn. 2024. PMID: 39535158 Review.

2

Focal prostate cancer therapy in the era of multiparametric MRI: a review of options and outcomes.

Heard JR, Naser-Tavakolian A, Nazmifar M, Ahdoot M. Heard JR, et al. Prostate Cancer Prostatic Dis. 2023 Jun;26(2):218-227. doi: 10.1038/s41391-022-00501-0. Epub 2022 Mar 4. Prostate Cancer Prostatic Dis. 2023. PMID: 35246609 Review.

3

Clinical and Preclinical Therapies for Bladder Cancer Following Bacillus Calmette-Guérin Failure.

Nazmifar M, Williams C, Naser-Tavakolian A, Heard J, Rosser C, Theodorescu D, Ahdoot M. Nazmifar M, et al. J Urol. 2023 Jan;209(1):32-48. doi: 10.1097/JU.0000000000002957. Epub 2022 Sep 6. J Urol. 2023. PMID: 36067380

4

Implementation and Validation of a High-fidelity Simulation Model for Surgical Resident Training: Management of Acute Intraoperative Hemorrhage during Robot-assisted Surgery.

Kheshvadjian M, Nazmifar M, Rawal R, Davood J, Castaneda P, Dadashian E, Dallmer J, Heard J, Masterson J, Lo E, Taich L, Naser-Tavakolian A, Kokorowski P, Ahdoot M. Kheshvadjian M, et al. Urology. 2024 Sep;191:185-192. doi: 10.1016/j.urology.2024.06.055. Epub 2024 Jun 25. Urology. 2024. PMID: 38936623

5

Noninvasive Tests for Bladder Cancer Detection and Surveillance: A Systematic Review of Commercially Available Assays.

Heard JR, Mitra AP. Heard JR, et al. Bladder Cancer. 2024 Mar 12;10(1):71-81. doi: 10.3233/BLC-230096. eCollection 2024. Bladder Cancer. 2024. PMID: 38993533 Free PMC article.

6

Patient preferences for life expectancy cutoffs for aggressive treatment in clinically localized prostate cancer.

Heard JR, Masterson JM, Luu M, Gale R, Spiegel B, Freedland SJ, Daskivich TJ. Heard JR, et al. Urol Oncol. 2024 Dec 13:S1078-1439(24)00772-5. doi: 10.1016/j.urolonc.2024.11.020. Online ahead of print. Urol Oncol. 2024. PMID: 39674764

7

Overtreatment of Prostate Cancer Among Men With Limited Longevity in the Active Surveillance Era.

Daskivich TJ, Luu M, Heard J, Thomas IC, Leppert JT. Daskivich TJ, et al. JAMA Intern Med. 2025 Jan 1;185(1):28-36. doi: 10.1001/jamainternmed.2024.5994. JAMA Intern Med. 2025. PMID: 39527047

8

The value of residency program characteristics changes throughout urology training.

Heard JR, Jeune KR, Masterson JM, Castaneda PR, Winer AG, Freedman AL. Heard JR, et al. Can J Urol. 2023 Dec;30(6):11724-11731. Can J Urol. 2023. PMID: 38104329

9

The New Urology Match: How Recent Innovations Including Virtual Interviews and Preference Signaling Have Changed Match Outcomes.

Heard J, Rawal RY, Amazan B, Jeune KR, Freedman A. Heard J, et al. Cureus. 2024 Jan 29;16(1):e53167. doi: 10.7759/cureus.53167. eCollection 2024 Jan. Cureus. 2024. PMID: 38420061 Free PMC article.

10

Female sexual health digital resources: women and health care providers need more options.

Dubinskaya A, Heard JR, Choi E, Cohen T, Anger J, Eilber K, Scott V. Dubinskaya A, et al. Among authors: heard jr. Sex Med Rev. 2023 Jun 27;11(3):174-178. doi: 10.1093/sxmrev/qead016. Sex Med Rev. 2023. PMID: 37102305 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

25 results

Search Page

Filters